Human Genome Sciences has come up with a ‘poison pill’ defence against the US$2.6 billion hostile bid from Britain’s GlaxoSmithKline (LON:GSK). Read More
Cynapsus Therapeutics Inc.: Cynapsus Therapeutics Retains US Investor Relations Firm - 17 May 2012, 09:00 am Cynapsus Therapeutics Inc. today announced that it has retained JSDC, Inc. to provide US-based investor relations services for the Company. Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease.
|
Edwards SAPIEN XT Transcatheter Valve Continues to Achieve Positive Patient Outcomes in 94 Center Post-Approval Stu... - 17 May 2012, 09:31 am Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that data from its post-approval study involving 94 European centers performing transcatheter aortic valve replacement demonstrated positive outcomes for high-risk patients treated with the Edwards SAPIEN XT transcatheter heart valve. |
Cytomedix Announces Expansion of Phase 2 Study to Treat Post-Acute Ischemic Stroke at Up to 15 U.S. Clinical Sites - 16 May 2012, 08:55 am Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, announced that the independent Data Safety Monitoring Board reviewing the safety data from the ongoing RECOVER-Stroke trial has recommended that the Phase 2 trial of ALD-401, a unique and differentiated stem cell population derived from patients' own bone marrow, can continue as designed. |
ProMetic Receives $4.2 Million Follow-on Order from Major Global Pharmaceutical Company - 15 May 2012, 08:49 am ProMetic Life Sciences Inc. announced today that it has received a $4.2 million follow-on purchase order pursuant to its ongoing long-term supply agreement entered into with a major global pharmaceutical company in 2009.
|
Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE Application for a Phase 2 Study of Therm... - 14 May 2012, 10:09 am Celsion Corporation, a leading oncology drug development company, today announced a joint resubmission with Philips Healthcare of an Investigational New Drug/Investigational Device Exemption application with the U.S. Food and Drug Administration for a Phase 2 clinical study of Celsion's ThermoDox® combined with Philips' Sonalleve® MR-HIFU technology for the treatment of prostate cancer metastases to the bone. |
Featured Company
|
Category: Energy
|
Featured Video
|
Posted on May 8 , 2012 at 12:00 am
|
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD - 14 May 2012, 08:54 am Ohr Pharmaceutical Inc. announced today that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors implicated in angiogenesis, has been awarded Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of the wet form of macular degeneration. |
BASi Reports Fiscal 2012 Second Quarter Results - 11 May 2012, 09:21 am Bioanalytical Systems, Inc. today announced financial results for the second quarter and first half of fiscal 2012. "BASi's second quarter results are not indicative of the performance we expect from the company. We are taking a variety of actions on the revenue and cost sides of our business that are designed to position the company for future success, and we are confident that our operating results will improve as a result," said President and CEO Tony Chilton.
|
Theratechnologies Inc.: New GRF Peptide TH1173 Enters Important Pre-Clinical Phase - 10 May 2012, 09:27 am Theratechnologies Inc. today announced that it has initiated the preclinical safety program for its second generation growth-hormone releasing factor (GRF) peptide, TH1173, with a view to begin clinical testing by early 2013.
|
BioSyent Pharma Launches Cathejellâ„¢ Jelly 2%; Shipments to Commence May 2012 - 9 May 2012, 04:25 pm BioSyent Inc. is pleased to announce that its subsidiary BioSyent Pharma Inc. has launched Cathejellâ„¢ Jelly 2% a Sterile Topical Anesthetic for the Canadian healthcare market. Cathejellâ„¢ Jelly 2% is an innovative pharmaceutical product that combines a sterile gel and lidocaine in a unique collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of a range of medical procedures.
|
Thallion and LFB Report Positive Top-Line Results from the Phase II SHIGATEC Trial at 'VTEC 2012' - 9 May 2012, 09:23 am Thallion Pharmaceuticals Inc. and LFB Biotechnologies announced that, earlier today, positive top-line results from the Phase II SHIGATEC trial evaluating the Company's Shigamabs® drug candidate as a treatment for Shiga toxin-producing E. coli [STEC] infection were presented at the 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012) in Amsterdam, The Netherlands.
|
17 May 2012, 08:49 AM
Human Genome Sciences devises poison pill to ward off GSK bi... by Proactive Investors
09 May 2012, 09:19 AM
GlaxoSmithKline: Will realism prevail as drugs giant goes ho... by Proactive Investors

| Name | Last | Change |
| $USD/CAD | 1.0174 | -0.0021 |
| $USD/GBP | 0.6323 | -0.0007 |
| $USD/EUR | 0.7877 | 0.0001 |
| $USD/AUD | 1.0143 | 0.0030 |
Stock Center Movers
| Cynapsus Therapeutics Inc. (CTH:CA) | $0.055 | 0.00% |
| Sirona Biochem Corp. (SBM:CA) | $0.065 | -7.14% |
| Visit the stock center | ||
| Name | Last | Change |
| Anooraq Resources Corporation (ATL:CA) | 0.30 | 0.00 |
| Liquor Group Wholesale Inc. (LIQR) | 0.021 | 0.00 |
| Physicians Healthcare Management Group Inc (PHYH) | 0.0006 | 0.00 |
| Ithaca Energy Inc. (IAE:CA) | 2.44 | -0.02 |
| Quest Rare Minerals Ltd (QSURD) |















